Early Triple Negative Breast Cancer remains an aggressive variant of all breast cancers, affecting those under 40 more and has a higher propensity for being in those with BRCA1/2 mutations. It represents about 15% of all breast cancers.

This week, we explore the benefit of immunotherapy (pembrolizumab), looking at improved complete pathological response as a surrogate marker for OS and the role of capecitabine in the adjuvant setting.

Studies discussed in the episode:

CREATE-X

KEYNOTE-522

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.

Hosted on Acast. See acast.com/privacy for more information.

Our second SABCS (San Antonio Breast Cancer Symposium) episode covers everything (else) you need to know from 2024.

In this episode, we dive into the role of trastuzumab deruxtecan in HR +ve, HER2 low cancers, perioperative atezolizumab in tnbc, the use of a novel ADC (SHR-A1811) and the role of tumour mutational burden in triple-negative cancer.

Studies discussed in the episode:

DESTINY-Breast06

Neoadj atezo

FASCINATE-N

KEYNOTE-522

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.

Hosted on Acast. See acast.com/privacy for more information.

Welcome back to Oncology for the Inquisitive Mind, where we head back to late 2024 and cover some pivotal trials and ideas from the San Antonio Breast Cancer Conference 2024.

This episode broadly covers hormone receptor-positive breast cancer and looks at another CDK comparison (real-world data). While the idea is not new, the potential implications from well-gathered "phase 4" data is a curious discussion point. Other topics include the ESR1 mutation and Imlunestrant, Patritumab Deruxtecan in hormone receptor-positive disease and the role of CTDNA in tumour burden and recurrence in early breast cancer

Studies discussed in the episode:

SOLTI-VALENTINE

EMBER 3

ctDNA in EBC

CDK Comparison

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.

Hosted on Acast. See acast.com/privacy for more information.